Anzeige
Mehr »
Donnerstag, 19.06.2025 - Börsentäglich über 12.000 News
+435 % Beteiligungsrendite durch TAO nach £5 Mio. Finanzierung und Bitcoin-Treasury-Strategie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
512 Leser
Artikel bewerten:
(2)

Pace® Analytical: Pace Life Sciences Announces Successful Pre-Approval Inspection From US FDA in Lebanon, NJ

Company confirms high standards for data integrity and quality systems

MINNEAPOLIS, MINNESOTA / ACCESS Newswire / May 20, 2025 / Pace® Life Sciences, a U.S.-based full-service FDA-registered GMP Analytical Testing laboratory and contract, research, development and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, announced today a successful Pre-Approval Inspection (PAI) from The Food & Drug Administration (FDA) highlighting company's commitment to reliable and accurate data.

pace life sciences logo

pace life sciences logo
pls full color logo

Lou Forcellini, Head of Quality Assurance at Pace® Life Sciences, stated, "The recent achievement for our Lebanon, NJ laboratory emphasizes our quality expertise and commitment to data integrity and compliance through our quality systems. The successful PAI demonstrates our ability to support customer programs from first-in-man studies to FDA approval, with flexibility to meet client needs." The Lebanon site, formerly Whitehouse Analytical Laboratories, was acquired by Pace® from Curia in 2024 and specializes in Container Closure Integrity Testing (CCIT), drug delivery physical testing, and package distribution testing.

"Our commitment to supporting clients from early-stage research and development to commercialization begins with ensuring quality data and testing," noted Dawn Von Rohr, President, Pace® Life Sciences. "The successful PAI recognition by the FDA validates the talent, expertise, and experience our team has with ensuring data integrity and regulatory compliance that makes us a trusted partner of top pharmaceutical companies." Pace® provides commercial release and stability testing for raw materials, active pharmaceutical ingredients (APIs), finished pharmaceuticals, and biologics, along with regulatory compliance, quality assurance, and process optimization support to the biotech and pharmaceutical industries.

In 2024, the FDA conducted an inspection of operations at the Pace® Life Sciences laboratories located in Oakdale, MN, and San Germán, Puerto Rico, with favorable outcomes from the harmonized quality systems, further demonstrating the company's continuous dedication to providing the highest quality results to clients.

Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.

###

ABOUT PACE® LIFE SCIENCES

Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. More at PACELIFESCIENCES.com.

ABOUT PACE®
Pace® makes the world a safer, healthier place. Pace® people are committed to advancing the science of the pharmaceutical and biotechnology industries in our Life Sciences laboratories and supporting businesses, industries, consulting firms, government agencies, and more through our Analytical Services laboratories. Pace® offers local-level service backed by a national laboratory network. For clients with in-house labs, Pace® provides a range of professional services to keep their operations moving forward. Pace® people work in partnership with clients by providing the service, science, and the data they need to make critical decisions that benefit us all. More at PACELABS.com.

Contact Information

Pam Bednar
Marketing Director
pam.bednar@pacelabs.com
612-297-0651

Brooke Schwartzel
Brand & Communications Manager
brooke.schwartzel@pacelabs.com
612-656-2241

.

SOURCE: Pace® Analytical



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pace-life-sciences-announces-successful-pre-approval-inspection-1029216

© 2025 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.